VJHemOnc Podcast cover image

CLL therapy: the latest trial updates and innovative novel therapies for the future

VJHemOnc Podcast

00:00

Development of Sanabrutinib and Acalabrutinib, Non-Covalent Binders, and the Results of the Asentral Trial

This chapter explores the developmental drugs Sanabrutinib and Acalabrutinib, their potential advantages over Ibrutinib, and the use of non-covalent binders. The results of the asentral trial comparing Bacalabrutinib to standard treatments for CLL are also discussed.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app